AstraZeneca plc’s (AZN) “Buy” Rating Reiterated at Liberum Capital
Liberum Capital reissued their buy rating on shares of AstraZeneca plc (LON:AZN) in a research note published on Tuesday, StockTargetPrices.com reports. The brokerage currently has a GBX 5,100 ($64.19) price target on the biopharmaceutical company’s stock.
A number of other equities analysts have also recently commented on AZN. Shore Capital restated a hold rating on shares of AstraZeneca plc in a report on Tuesday, January 3rd. Deutsche Bank AG lowered their target price on AstraZeneca plc from GBX 6,000 ($75.52) to GBX 5,500 ($69.23) and set a buy rating for the company in a report on Monday, February 6th. HSBC Holdings plc lowered their target price on AstraZeneca plc from GBX 4,700 ($59.16) to GBX 4,500 ($56.64) and set a hold rating for the company in a report on Tuesday, February 7th. Kepler Capital Markets set a GBX 5,000 ($62.93) price target on AstraZeneca plc and gave the company a buy rating in a research report on Thursday, December 29th. Finally, Berenberg Bank reduced their price target on AstraZeneca plc from GBX 5,500 ($69.23) to GBX 5,450 ($68.60) and set a buy rating on the stock in a research report on Tuesday, February 21st. Five equities research analysts have rated the stock with a sell rating, six have assigned a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company. AstraZeneca plc currently has an average rating of Hold and an average target price of GBX 5,057.40 ($63.66).
Shares of AstraZeneca plc (LON:AZN) opened at 4566.00 on Tuesday. The stock has a 50 day moving average of GBX 4,808.85 and a 200-day moving average of GBX 4,576.87. AstraZeneca plc has a 52 week low of GBX 3,680.00 and a 52 week high of GBX 5,505.00. The stock’s market cap is GBX 57.77 billion.
COPYRIGHT VIOLATION NOTICE: This story was first posted by Marea Informative and is the property of of Marea Informative. If you are accessing this story on another site, it was illegally stolen and reposted in violation of U.S. & international copyright & trademark law. The legal version of this story can be viewed at http://www.mareainformativa.com/astrazeneca-plc-azn-a-comprar-clasificacion-de-reafirmado-en-liberum-capital/108762/.
About AstraZeneca plc
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Stock Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related stocks with our FREE daily email newsletter.